Forecast 2026 Global Pharmaceutical Sales Ranking TOP15 (above)

As the pharmaceutical industry enters a new decade, global pharmaceutical giants are busy rolling out new drugs, reorganizing to focus on innovative products and new technologiesDespite the challenges from the new crown, industry analysts see the growth potential of many giantsAccording to Evaluate Pharma's consensus forecast, Roche will lead other big pharmaceutical companies in its 2026 sales list, driven by new products of oncology, multiple sclerosis and haemophiliaPfizer, Johnson and Johnson, Novartis, AbbVie and Mercado will follow suit, with more than $50 billion in revenue from drug sales in 2026High sales don't mean the fastest growthAnalysts believe AstraZeneca and BMS will have the highest growth rates, with annual growth forecasts of 8.47 per cent and 8.23 per cent in 2019-2026, respectivelyis a detailed description of the global pharmaceutical giants' near- to medium-term outlook report: 1, Roche's 2019 sales: $48.2 billion Expected 2026 sales: $61.9 billion 2019-2026 CAGr: 3.62% of Roche topped the list is somewhat surprising because its three ace biologics (Anvetin, Herceptin, Merlot) will lose 9.6 billion Swiss francs from the competition for biologically similar drugsBut new drugs are expected to catch up, and not just fill the gapRoche also has an extensive oncology portfolioThis year, Tecentriq was approved for first-line treatment of liver cancer, Tecentriq single drug was approved for first-line treatment of non-small cell lung cancer, tecentriq combined chemotherapy new complementary treatment significantly improved the prognosis of patients with triple-negative breast cancerIn addition, Tecentriq treats a variety of other types of tumors and is also in Phase III clinical developmentCredit Suisse points out that Tecentriq will sell $7 billion in cancer-assisted (postoperative) treatment aloneIn addition, new molecular entities are also coming, such as AKT inhibitor ipatasertibBut Roche is not just focused on cancerOne of the most successful products in the company's history was a neuroscience drug: Ocrevus, a multiple sclerosis drug that has been infusions only twice a yearAs of the first quarter of 2020, Ocrevus has a 21% market share in the U.Smarket, with more than 40% of new and converted patients Short infusion times, twice a year, will help Ocrevus gain a foothold in the market In the field of neuroscience, Roche also has risdiplam, which will be the first oral spinal muscular dystrophy (SMA) drug Evaluate Pharma had previously forecast sales of $803 million in 2024 Meanwhile, IL-6 antibody satralizumab is awaiting the FDA's decision Other growth drivers for Roche include hemophilia drug Hemlibra, which reported first-quarter sales of CHF 521 million, up 146 percent year-on-year In defense of the haemophilia franchise, Roche acquired Gene Therapy company Spark Therapeutics 2, Pfizer 2019 sales: $46.1 billion Projected 2026 sales: $56.1 billion 2019-2026 CAGr: 2.83% According to Evaluate forecast, Pfizer's annual growth rate in 2019-2026 will be 2.83 percent, with sales more than $5 billion higher than in 2019 To do so, Pfizer will certainly need to rely on its lucrative biopharmaceutical brand, which grew an impressive 12 per cent in the first quarter and generated revenues of more than $10bn Pfizer's five core products, Vyndaqel, Eliquis, Ibrance, Prevnar and Xeljanz, will provide a bright future for the company The five products won't face patent losses until 2025, giving Pfizer plenty of room to identify strategic acquisitions or further investment pipelines to sustain growth in the coming years In the pipeline, the new generation 20-price pneumonia vaccine will be prevnar 13 upgrade products, in Phase III clinical success, is expected to submit a listing application by the end of the year These strong products and pipelines will boost Pfizer's growth by 3 percent after the split But the split didn't go well, with EU regulators saying in April that Mylan and Upjohn overlapped in cardiovascular, musculoskeletal, neurological and urinary diseases The U.S review continues and has been delayed by the outbreak 3, Johnson and Johnson 2019 sales: $42.4 billion Estimated 2026 sales: $54.6 billion 2019-2026 COMPOUND annual growth rate: 3.75% Of Johnson and Johnson in the pharmaceutical business, due to the introduction of new products and brand expansion, is expected to grow rapidly in the next few years, 2026 sales will exceed 54 billion U.S dollars, among the world's top three Johnson and Johnson's pharmaceutical business, the company's largest division, generated $42.2 billion in revenue last year Consumer health revenue was $13.9 billion and medical device revenue was $26 billion The pharmaceutical business was not only the biggest sales last year, but revenue growth was also strongest, at 5.8 per cent Oncology has been a strong driver in the pharmaceutical business, with franchise revenue up 11.9 percent to $10.7 billion in 2019 In addition to tumors, Johnson and Johnson Immunology generated nearly $14 billion in 2019, up 7.9 percent from the previous year Johnson and Johnson Neuroscience franchise revenue rose 6.6 percent to $6.3 billion, while sales of cardiovascular, metabolic and other drugs fell 9.7 percent to $5.2 billion Some of Johnson's heavyweights are growing strongly, but executives believe there are more opportunities in the pipeline In 2020, Zytiga's follow-up product, Erleada, the depression injection Spravato, the blood cancer drug Imbruvica, the psoriasis drug Tremfya, the cancer drug Darzalex and the diabetes drug Invokana, will achieve potential brand expansion In addition, the company has just received approval for a new Ebola vaccine in the European Union and may be approved by the end of the year for the HIV drug rilpivirine Industry analysts are also very bullish about the prospects for their hematological assets, CAR-T Therapy JNJ-4528 and bispecific antibody teclistamab 4, Novartis 2019 sales: $46.08 billion Projected 2026 sales: $54.25 billion 2019-2026 CAGr: 2.36% Novartis has a broad portfolio of star drugs, including immunology, cardiology, neuroscience, oncology, and more The company is aggressively expanding its business to include both new indications and new treatments In the past few years, Novartis has entered several new areas: through the acquisition of Advanced Accelerator S and Endocyte to establish a radioactive drug business, through the acquisition of AveXis into the gene therapy space, through the acquisition of The Medicines Company into the RNA treatment field and the expansion of the heart portfolio At the same time, the company sold its over-the-counter drug business to its joint venture partner, GlaxoSmithKline (GSK), and divested its ophthalmology business, Alcon, although it tried to abandon its U.S franchise of Sandex's oral generics business but failed to get approval from the U.S Federal Trade Commission within the scheduled time frame Novartis' leading portfolio is IL-17 Inhibitor Cosentyx, with sales of $3.55 billion in 2019, up 25% year-on-year But the drug could face some new competition from Theaves IL-23 inhibitor Skyrizi, which beat Cosentyx in a psoriasis head-to-head study Another major growth driver in Novartis was the heart-decay drug Entresto, which sold $1.73 billion in 2019, up 68 percent from a year earlier In a Phase III trial last year, Entresto missed a statistical lysaof in reducing death rates and emergency hospitalization rates for patients with reduced blood score reduction (HFpEF) heart failure (HFpEF), but after talking to the FDA and applying for new indications could help Entresto achieve its $5 billion annual sales goal Then there's SMA gene therapy Zolgensma Now, the drug has reached a bottleneck in the U.S., treating about 100 patients per quarter with sales of $200 million In the first half of this year, the drug was also approved in Japan and Europe, and Novartis is looking forward to these approvals to help achieve sales growth The company is also developing an injection of Zolgensma into the vertebral tube, which could steal market share from The Ong Spinraza Oncology is a key area of Novartis, and Kisqali has been accelerated to show that it can help HR/HER2-metastatic breast cancer survive longer, regardless of menopausal status The drug will now compete with Pfizer's market-leading Ibrance and Lilly Verzenio Novartis is also testing Kisqali as an auxiliary treatment for HR/HER2-early-stage breast cancer, which is expected to be announced in 2022 In addition, MET inhibitor Tabrecta has just received FDA approval to treat MET mutant metastatic non-small cell lung cancer and will compete with Merck Tepmetko On the pipeline side, Novartis has cholesterol-lowering therapy inclisiran Despite the flat performance of the PCSK9 antibody drug on the market, Novartis hopes to build a heavyweight product based on business experience in the field of cardiology and inclisiran's novel RNAi mechanism and low frequency of administration In addition, the use of the leukemia drug Arzerra to redevelop the use of the drug for the treatment of multiple sclerosis, ofatumab, has the potential to become Roche Ocrevus's class challenger Novartis is also counting on the Chinese market to drive its growth In the five years to 2024, Novartis plans to approve more than 50 new drugs in China, and hopes to double its current annual sales of $2.2 billion For the future, Novartis aims to submit applications simultaneously in China and the U.S and Europe 5, AbbVie 2019 sales: $32.35 billion Estimated 2026 sales: $53.56 billion 2019-2026 CAGr: 1.84% In this list, AbbVie changed the most from last year, thanks to the acquisition of Aer Lingus But Evaluate expects that even after a large-scale acquisition, AbbVie is not without the possibility of considering further action AbbVie's annual growth rate is 1.84 per cent in 2019-2026, so more deals may be necessary After all, competition for Humira's biosimilars will be fierce, and after years of defending the franchise, Humira will face competition in the U.S for many biosimilar stakes starting in early 2023 In Europe, Humira is already competing with biosimilars, and sales are falling AbbVie is selling Humira's follow-up products, Skyrizi and Rinvoq, to treat plaque psoriasis and rheumatoid arthritis, respectively, and expects more indications in the future Rick Gonzalez, the company's chief executive, told JPMorgan's healthconference conference earlier this year that the drugs could lead to a sales spike of nearly $20 billion over Humira in the future While Humira's loss of exclusive rights in 2023 will hurt, analysts at RBC Capital Markets believe AbbVie will continue to grow because its pipeline is currently undervalued and visibility and confidence will improve over the next few years In addition, the company has just signed a bispecific antibody agreement with Genmab and intends to do more 6, Mercado 2019 sales: $40.9 billion Projected 2026 sales: $51.96 billion 2019-2026 COMPOUND annual growth rate: 3.48 percent Mercadon heavy-weight immuno-oncology product Keytruda is continuing to drive the company's revenue trajectory, but CEO Ken Fraerzi is working behind the scenes to ensure the company has other opportunities beyond this fast-growing cancer drug Mercado's sales are forecast to grow to $52 billion in 2026, up from $46.8 billion last year, thanks in large part to Keytruda Evaluate forecasts that Keytruda will have $24.3 billion in sales in 2026, overtaking Humira as the best-selling drug of 2026 The numbers are likely because Mercadon has been expanding Keytruda's market since the FDA first approved Keytruda for melanoma in 2014 Currently, the treatment of indications has covered 17 types of cancer, including 2 open-ended cancer type indications, that is, not based on the location of the cancer in the body, but based on the tumor what biomarkers are found However, Ken Frazier and his team of executives are well aware that they are under pressure to diversify their product lines and pipelines In the fourth quarter of last year's earnings report, Ken Frazier said the company would spin off its women's health and biosimilars division to focus more on building prescription drug pipelines 7, Sanofi 2019 sales: $40.17 billion Projected 2026 sales: $49.5 billion 2019-2026 CAGr: 3.03% last September, CEO Paul Hudson announced his vision for Sanofi in December This is an ambitious strategic shift: the company will redouble its efforts in areas it believes can be successful and shrink or exit other areas The company plans to scale back research and development in the diabetes and cardiovascular sectors and invest resources in cancer, rare diseases, vaccines and other growth prospects Other growth prospects here are largely for Dupixent, which plans to launch Dupixent in new markets and new uses in the coming years, with the goal of peaking sales at 10 billion euros Sanofi is also expanding oncology, and this year it has received approval for the multiple myeloma drug Sarclisa, the company's first fully owned oncology drug in a decade Sanofi has also invested heavily in vaccines In June, the company pledged $554 million for a new manufacturing plant in eastern France The change also means Sanofi will lay off workers in its long-standing areas, namely diabetes and cardiovascular disease The company also said it would take the PCSK9 cholesterol-lowering drug Pralue.